Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder?: A Systematic Review of Clinical Trials and Cost-Effectiveness Studies

Rosenblat, Joshua D., Lee, Yena, McIntyre, Roger S. · 2017 · The Journal of Clinical Psychiatry

Abstract

OBJECTIVE: Pharmacogenomic testing has become scalable and available to the general public. Pharmacogenomics has shown promise for predicting antidepressant response and tolerability in the treatment of major depressive disorder (MDD). In theory, pharmacogenomics can improve clinical outcomes by guiding antidepressant selection and dosing. The current systematic review examines the extant literature to determine the impact of pharmacogenomic testing on clinical outcomes in MDD and assesses its cost-effectiveness. DATA SOURCES: The MEDLINE/PubMed and Google Scholar databases were systematically searched for relevant articles published prior to October 2015. Search terms included various combinations of the following: major depressive disorder (MDD), depression, mental illness, mood disorder, antidepressant, response, remission, outcome, pharmacogenetic, pharmacogenomics, pharmacodynamics, pharmacokinetic, genetic testing, genome wide association study (GWAS), CYP450, personalized medicine, cost-effectiveness, and pharmacoeconomics. STUDY SELECTION: Of the 66 records identified from the initial search, relevant clinical studies, written in English, assessing the cost-effectiveness and/or efficacy of pharmacogenomic testing for MDD were included. DATA EXTRACTION: Each publication was critically examined for relevant data. RESULTS: Two nonrandomized, open-label, 8-week, prospective studies reported overall greater improvement in depressive symptom severity in the group of MDD subjects receiving psychiatric care guided by results of combinatorial pharmacogenomic testing (GeneSight) when compared to the unguided group. One industry-sponsored, randomized, double-blind, 10-week prospective study reported a trend for improved outcomes for the GeneSight-guided group; however, the trend did not reach statistical significance. Another industry-sponsored, randomized, double-blind, 12-week prospective study reported a 2.5-fold increase in remission rates in the CNSDose-guided group (P < .0001). One naturalistic, unblinded, industry-sponsored study showed clinical improvement when pharmacogenomics testing guided prescribing; however, this study lacked a control group. A single cost-effectiveness study concluded that single gene testing was not cost-effective. Conversely, a separate study reported that combinatorial pharmacogenomic testing is cost-effective. CONCLUSIONS: A limited number of studies have shown promise for the clinical utility of pharmacogenomic testing; however, cost-effectiveness of pharmacogenomics, as well as demonstration of improved health outcomes, is not yet supported with replicated evidence.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.15r10583

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Still being checked.

Cited by

See all 145

Metadata

Authors
Rosenblat, J. D., Lee, Y., & McIntyre, R. S.
Affiliations
  • University of Toronto (CA)
  • University Health Network (CA)
Venue
The Journal of Clinical Psychiatry
Published
2017-06-28
Volume
78
Issue
06
Pages
720-729
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2562914031
Cited by
138
References
0
Citations by year
2026: 2 · 2025: 10 · 2024: 4 · 2023: 16 · 2022: 7 · 2021: 22 · 2020: 15 · 2019: 24 · 2018: 23 · 2017: 15
FWCI
22.40
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
pharmacogenetic testing, major depressive disorder, antidepressant response, antidepressant tolerability, cytochrome P450, personalized medicine, cost-effectiveness, depression remission, antidepressant selection, genetic testing
MeSH terms
Pharmacogenomic Testing, Clinical Trials as Topic, Cost-Benefit Analysis, Depressive Disorder, Major, Major Depressive Disorder, Humans, Outcome and Process Assessment, Health Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder?: A Systematic Review of Clinical Trials and Cost-Effectiveness Studies. https://app.cochat.ai/papers/10.4088/jcp.15r10583
The paper
Rosenblat, J. D., Lee, Y., & McIntyre, R. S. (2017). Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder?: A Systematic Review of Clinical Trials and Cost-Effectiveness Studies. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.15r10583

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.